---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-019760"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2025-07-16T23:59:59+00:00"
generated_at: "2026-05-18T06:18:30.374754+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Dermata Therapeutics stockholders approve reverse stock split and director elections at 2025 meeting

## Summary
- Stockholders elected Mary Fisher and Andrew Sandler as Class I directors for three-year terms.
- Ratified Baker Tilly US, LLP as independent auditor for FY2025 with 3,229,829 votes for.
- Approved issuance of shares underlying warrants from Jan 2025 SPA and March 2025 inducement letter (over 20% of outstanding).
- Authorized reverse stock split at ratio between 1:2 and 1:30, with board to determine exact ratio.

## SEC filing metadata
- accession: 0001641172-25-019760
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2025-07-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000164117225019760/0001641172-25-019760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000164117225019760/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-019760
- JSON: https://secwatch.observer/filing/0001641172-25-019760.json
- Plain text: https://secwatch.observer/filing/0001641172-25-019760.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.